Simpler, Less Expensive Test for Ulcer Bug

Publication
Article
OncologyONCOLOGY Vol 12 No 1
Volume 12
Issue 1

Researchers from the University of Wurzburg in Germany have determined that a simple antibody test may be as effective in detecting Helicobacter pylori infection as the more invasive procedures that are currently used. They reported their findings

Researchers from the University of Wurzburg in Germany have determined that a simple antibody test may be as effective in detecting Helicobacter pylori infection as the more invasive procedures that are currently used. They reported their findings in the December 1997 issue of the Journal of Clinical Microbiology.

In the study, the researchers compared the sensitivity of a test for Hpylori-specific immunoglobulin G (IgG) antibodies with the standard tests in clinical practice. The antibody test had a 98% sensitivity, correctly diagnosing 58 of the 59 patients diagnosed by standard methods.

“The current gold standard tests in clinical practice, endoscopy for histology and the rapid urease test, are limited by their relatively high costs and the need for invasive procedures,” say the researchers. “Determination of antibodies against H pylori presents a relatively simple diagnostic method, with kits that can be used to perform this method now...readily available from commercial sources.”

Helicobacter pylori is a bacterium that lives in the harsh acidic environment of the stomach. The cause of most duodenal ulcers and an estimated 70% to 80% of gastric ulcers, H pylori is considered to be a risk factor for stomach cancer. 

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.